PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call

Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call

MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time.

The call will be webcast and may be accessed at Pacific Biosciences’ website at: .

Date: February 10, 2021

Time: 4:30pm ET

Listen via Internet:

Toll-free: 888.366.7247

International: 707.287.9330

Conference ID: 8096067

Replay:

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit and follow .

Contact: Pacific Biosciences

Trevin Rard

650.521.8450



EN
27/01/2021

Underlying

PACBPacific Biosciences of California Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomic...

PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer MENLO PARK, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher, a recognized leader in epigenetics tools, has joined the PacBio Compatible program. The partnership brings EpiCypher’s CUTANA® Hia5 enzy...

September 3, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces Second Quarter 2025 Financial Results

PacBio Announces Second Quarter 2025 Financial Results MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results:  Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating...

August 7, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio to Present at Upcoming Investor Conferences

PacBio to Present at Upcoming Investor Conferences MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 2:30 PM ET in Boston, MAMorgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 12:20 PM ET in New York, NY Live webcasts of the events can be accessed at the company’s in...

August 6, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

Nature Methods Paper Leverages PacBio Sequencing Technology to Develop...

Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of describing a new, comprehensive truth-set of genomic variation whi...

August 4, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in...

PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a significant advancement for global genomic equity. Researchers have published the first Arab human pangenome in , powered in large part by PacBio’s HiFi long-read sequencing. The study, led by Mohammed Bin Rashid Univers...

July 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch